Sofetabart mipitecan(Sofe-M)靶向FRα治疗高级别卵巢癌:首次人体1期研究结果
全人群客观缓解率50.5%(95%CI 40.5, 60.4),中位无进展生存期8.1个月(95%CI 6.4, 8.5),未观察到角膜病变或≥3级神经病变,支持3 mg/kg作为3期推荐剂量。
要点
- 全人群ORR 50.5%,FRα<75%与≥75%亚组分别为44.4%和56.5%。
- 未观察到角膜病变或≥3级神经病变,3 mg/kg组≥3级治疗相关TEAE率35.3%。
- 3 mg/kg被推荐为3期剂量,据此开展FRAmework-01试验。
核心结论
- Sofe-M耐受性良好,尤其无角膜病变和高级别神经病变,在重度经治HGOC中显示持久临床活性,且不受FRα表达水平或既往MIRV影响。
- 数据支持3 mg/kg为推荐3期剂量,并构成FRAmework-01试验的基础。
研究设计与样本
- 多中心、开放标签、首次人体1期试验,评估Sofe-M用于HGOC,不限FRα表达水平,允许既往MIRV治疗。
- 19例(18.1%)有既往MIRV暴露,54例(51.4%)肿瘤FRα表达<75%(≥2+强度)。
- 研究注册号:1期NCT06400472;FRAmework-01 NCT07213804。
主要发现
- 全人群ORR为50.5%(95%CI 40.5, 60.4);3 mg/kg组ORR为58.8%(95%CI 32.9, 81.6)。
- FRα<75%组ORR为44.4%(95%CI 30.9, 58.6),FRα≥75%组为56.5%(95%CI 41.1, 71.1)。
- 既往MIRV暴露患者ORR为57.9%(95%CI 33.5, 79.7)。
- 中位无进展生存期8.1个月(95%CI 6.4, 8.5),中位随访12.9个月(95%CI 10.6, 15.2)。
- 最常见TEAE为恶心(64.8%)、疲乏(56.2%)和贫血(47.6%);未观察到角膜病变或≥3级神经病变。
关键数值与推荐
- 3 mg/kg与4 mg/kg组≥3级治疗相关TEAE发生率分别为35.3%和56.4%。
- 因TEAE终止治疗者11例(10.5%)。
- 推荐3期剂量为3 mg/kg每21天一次。
临床怎么用
- Sofe-M可用于重度经治HGOC,包括FRα低表达及既往MIRV暴露患者,3 mg/kg为后续3期研究剂量。
- 用药期间需关注恶心、疲乏和贫血等常见不良事件,该药未见角膜病变和高级别神经病变。
局限性
- 随访时间有限(中位随访12.9个月),长期安全性与生存获益尚未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Folate receptor alpha (FRα) is overexpressed in most high-grade ovarian cancers (HGOC), but use of the FRα-targeting drug mirvetuximab soravtansine-gynx (MIRV) is limited by expression-level restrictions and toxicity profile. Sofetabart mipitecan (Sofe-M) is a novel FRα-targeting antibody-drug conjugate designed to overcome these barriers. Here we report safety, efficacy, and pharmacokinetics from the first-in-human phase 1 study. PATIENTS AND METHODS: This multicenter, open-label, phase 1 trial evaluated Sofe-M in patients with HGOC, regardless of FRα expression level. Prior MIRV treatment was permitted. RESULTS: One-hundred-five patients with HGOC, the majority of whom were platinum resistant, received Sofe-M at 2, 3, 4 or 6 mg/kg every 21 days. Median age was 63.0 years, median number of prior treatments was 5.0 (1-11), 19 (18.1%) patients had prior MIRV, and 54 (51.4%) had tumor FRα expression <75% at ≥2+ intensity. Overall response rate was 50.5% (95% CI 40.5, 60.4) for all patients, 58.8% (95% CI 32.9, 81.6) at 3 mg/kg, 44.4% (95% CI 30.9, 58.6) for FRα <75%, 56.5% (95% CI, 41.1, 71.1) for FRα ≥75%, and 57.9% (95% CI 33.5, 79.7) for patients with prior MIRV exposure. Median progression-free survival was 8.1 months (95% CI 6.4, 8.5) and median follow-up was 12.9 months (95% CI 10.6, 15.2). Most common treatment-emergent adverse events (TEAEs) were nausea (64.8%), fatigue (56.2%), and anemia (47.6%). No keratopathies or grade ≥3 neuropathy were observed. At 3 and 4 mg/kg, the rate of Grade ≥3 treatment-related TEAEs was 35.3% and 56.4%, respectively. Treatment discontinuation due to TEAEs occurred in 11 patients (10.5%). CONCLUSIONS: Sofe-M demonstrated a favorable tolerability profile, notably absent of keratopathy and high-grade neuropathy, with durable clinical activity in heavily pretreated HGOC patients regardless of FRα expression level or prior MIRV. These data support 3 mg/kg as the recommended phase 3 dose and provide the basis for the FRAmework-01 trial. CLINICAL TRIAL REGISTRATION NUMBER: Phase 1 (NCT06400472); FRAmework-01 (NCT07213804).
引用
- Ray-Coquard I, O'Malley DM, Oaknin A, et al. Sofetabart mipitecan, an antibody drug conjugate targeting folate receptor alpha, in high grade ovarian cancer: Results from the first-in-human phase 1 study. Ann Oncol. 2026. PMID: 42849725. doi:10.1016/j.annonc.2026.10.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。